Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658638 | 0.75 | MEN1 (0.41) | LMNANAMPT | |
| SCHEMBL18496317 | 0.72 | CYP2D6 (0.54) | ALDH1A1HPGDLMNANAMPTHSD17B10 | |
| SCHEMBL18496262 | 0.72 | CYP2D6 (0.54) | ALDH1A1HPGDLMNANAMPTHSD17B10 | |
| SCHEMBL18496264 | 0.72 | CYP2D6 (0.54) | ALDH1A1HPGDLMNANAMPTHSD17B10 | |
| SCHEMBL19658633 | 0.72 | MTNR1A (0.49) | ALDH1A1LMNANAMPT | |
| SCHEMBL1746604 | 0.72 | — | — | |
| SCHEMBL27540587 | 0.71 | — | — | |
| SCHEMBL6380672 | 0.71 | LMNA (0.38) | ALDH1A1HPGDLMNA | |
| SCHEMBL19652066 | 0.71 | NAMPT (0.37) | HPGDLMNANAMPTTSHR | |
| SCHEMBL20324016 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943625-B2 | Myeloperoxidase inhibitors; neuroinflammatory disorders; COPD; 3-(2-Ethoxy-2-methylpropyl)-2-thioxanthine | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-20090131459-A1 | 2-Thioxanthine Derivatives Acting as MPO-Inhibitors | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| EP-2029598-A1 | 2-THIOXANTHINE DERIVATIVES ACTING AS MPO-INHIBITORS | Astra Zeneca AB (SE) | 2009-03-04 | — | — | EP | disclosed |
| US-20080221133-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| WO-2007142576-A1 | 2-THIOXANTHINE DERIVATIVES ACTING AS MPO-INHIBITORS | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131459-A1 | 2-Thioxanthine Derivatives Acting as MPO-Inhibitors | MPO, SERPINB1, XDH | ALDH1A1 132/4885HPGD 415/4885LMNA 3052/4885 |
| US-20080221133-A1 | Compounds | C1R, C1S, AKR1C3 | ALDH1A1 169/4885HPGD 2291/4885LMNA 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.